NLG919
Product Specifications
Background
NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM) .1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
Conjugation
Unconjugated
Buffer
White solid
Storage Conditions
-20°C
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
